News Release

Takeda to Acquire Paradigm Therapeutics

OSAKA, JAPAN and CAMBRIDGE UK March 12, 2007 --- Takeda Pharmaceutical Company
Limited (“Takeda”) today announced that Takeda and Paradigm Therapeutics Limited (“Paradigm”)
agreed on March 12, 2007 to the acquisition of Paradigm by Takeda. Paradigm shareholders were
advised by Avlar BioVentures Limited. Financial terms were not disclosed. Subject to completion, which
is expected to occur within a few weeks, Paradigm will become a subsidiary of Takeda Europe Holdings
B.V., a wholly owned subsidiary of Takeda. Additionally, Paradigm will be renamed Takeda Cambridge
Limited, and Paradigm’s subsidiary in Singapore will be renamed Takeda Singapore Pte Limited.

Founded in 1999 by University of Cambridge researchers, Paradigm has established world-class

target identification and validation capabilities based on genetic engineering and in vivo pharmacology.
Using their capabilities, Paradigm has already developed a promising pipeline of novel drug discovery
targets and compounds in key areas of unmet medical need including pain, CNS disorders, prostate and
breast cancer, diabetes, hyperlipidemia, and obesity.

With this merger, which replaces and builds upon Takeda and Paradigm’s 2005 CNS therapeutic
area alliance, Paradigm’s technologies and researchers will be integrated into Takeda and will help to
accelerate multiple scientific processes such as the validation of drug targets derived from genomic
research, the creation of animal models reflecting the human pathologic conditions, and the optimization
of drug candidates.

“Takeda have been an excellent partner in our CNS collaboration and this deal represents a logical
and positive extension to that. The company looks forward to continuing with its drug discovery and
development activities within the global reach and long term planning horizons of Takeda,” said Alastair
Riddell, CEO of Paradigm.

“We are very excited with this deal, which will add to Takeda another research base equipped with
the state-of-the-art technologies expected to further improve Takeda’s research efficiency,” said
Yasuchika Hasegawa, President of Takeda. “We now have research functions in Japan, the U.S., Europe,
and in Singapore where Paradigm has its subsidiary. This acquisition surely represents our initiatives for
establishing global research infrastructures and for pursuing the world’s highest standard of productivity,
which we believe will support enhancement of our R&D pipeline as source for future growth, and the
 realization of our goal to become a truly world-class pharmaceutical company.”

###

<About Paradigm>
Paradigm is a private venture capital backed drug discovery and development company located on the
Cambridge Science Park in Cambridge UK and Biopolis in Singapore. Paradigm acquired Amedis
Pharmaceuticals in December 2004, and Paradigm signed collaboration agreement in June 2005 with Takeda
Pharmaceutical Company.

<About Takeda>
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals.
As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is
committed to striving toward better health for individuals and progress in medicine by developing superior
pharmaceutical products.

###

Contacts: Takeda Pharmaceutical Company Limited

Mr. Seizo Masuda
Corporate Communications Dept.
Tel: +81 (0) 6 6204 2060

Paradigm Therapeutics Limited

Dr. Mark Carlton
Chief Scientific Officer
Tel: +44 12 23 477 910

Paradigm Therapeutics Singapore Pte Limited

Dr. Ian Gray
Director of Research
Tel: +65 677 11 300